Effect of topical application and intraperitoneal injection of oregonin on atopic dermatitis in NC/Nga mice.
The diarylheptanoid, oregonin (ORE), which was isolated from the bark of Alnus japonica Steudel that grows natively in Korea, has been known to exert antioxidative, anti-inflammatory, anti-cancer and immune response inhibitory effects. The antioxidative effect of ORE was observed on the superoxide and 1,1-diphenyl-2-picrylhydrazyl radical, as well as on the expression of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-treated RAW264.7 macrophages. The statistically significant inhibitory action of ORE against production of cytokines induced by bacterial products or by interleukin (IL)-1beta, free radicals and nitrogen species, and a corresponding increase in cellular calcium concentration because of ORE were confirmed in bone marrow and spleen dendritic cells that are known to play important functions in the development and advancement of atopic dermatitis (AD). It was thus expected that ORE would exert a beneficial effect in the treatment of AD. A study on the pharmaceutical benefits of ORE against AD has not yet been conducted in vivo. We therefore used an in vivo AD animal model, namely the NC/Nga mice, and by applying ORE onto the animals through skin application as well as intraperitoneal injection, we attempted to evaluate the benefits of ORE in this system. Evaluation of ORE was conducted by following the SCORE method to score the effect, as well as by measuring the Th2 cytokines IL-4, IL-5 and IL-13 levels from serum and lymphocytes, and IgE and eosinophil levels from serum. Additionally, the expression of mRNA and protein levels was estimated using real-time polymerase chain reaction and Western blotting analysis. The following categories of clinical evaluation, Th2 cytokines IL-4, IL-5 and IL-13 values, serum IgE levels, serum eosinophil levels, and mRNA and protein expression levels of iNOS and COX-2, were evaluated from topical application and intraperitoneal injection groups of ORE. The effects of ORE on AD in NC/Nga mice were confirmed as being similar to the positive control group, while a significant difference with the negative control group was observed. The results presented in this report suggest that ORE might be beneficial in the treatment of AD.
Choi
Sun Eun
SE
College of Pharmacy, Chung-Ang University, Seoul, South Korea.
Jeong
Mi Sook
MS
Kang
Myung Joo
MJ
Lee
Do Ik
DI
Joo
Seong Soo
SS
Lee
Chung Soo
CS
Bang
Hyoweon
H
Lee
Mi-Kyung
MK
Myung
Soon-Chul
SC
Choi
Young Wook
YW
Lee
Kap-Sok
KS
Seo
Seong Jun
SJ
Lee
Min Won
MW
D000287:Administration, Topical; D029661:Alnus; D000818:Animals; D051546:Cyclooxygenase 2 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000378:metabolism; D036381:Diarylheptanoids / Q000008:administration & dosage* / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D007073:Immunoglobulin E / Q000097:blood; D007274:Injections, Intraperitoneal; D051379:Mice; D008815:Mice, Inbred Strains; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010936:Plant Extracts / Q000008:administration & dosage* / Q000627:therapeutic use*; D017382:Reactive Oxygen Species / Q000378:metabolism; D016896:Treatment Outcome
D016207:Cytokines; D036381:Diarylheptanoids; D010936:Plant Extracts; D017382:Reactive Oxygen Species; C409456:oregonin; D007073:Immunoglobulin E; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2